EP3790578A4 - Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof - Google Patents

Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof Download PDF

Info

Publication number
EP3790578A4
EP3790578A4 EP19800357.6A EP19800357A EP3790578A4 EP 3790578 A4 EP3790578 A4 EP 3790578A4 EP 19800357 A EP19800357 A EP 19800357A EP 3790578 A4 EP3790578 A4 EP 3790578A4
Authority
EP
European Patent Office
Prior art keywords
rmva
vaccines
preparation
methods
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19800357.6A
Other languages
German (de)
French (fr)
Other versions
EP3790578A1 (en
Inventor
Felix WUSSOW
Don J. Diamond
Heidi CONTRERAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of EP3790578A1 publication Critical patent/EP3790578A1/en
Publication of EP3790578A4 publication Critical patent/EP3790578A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19800357.6A 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof Withdrawn EP3790578A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670656P 2018-05-11 2018-05-11
PCT/US2019/031866 WO2019217922A1 (en) 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof

Publications (2)

Publication Number Publication Date
EP3790578A1 EP3790578A1 (en) 2021-03-17
EP3790578A4 true EP3790578A4 (en) 2022-04-06

Family

ID=68467105

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19800357.6A Withdrawn EP3790578A4 (en) 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof

Country Status (5)

Country Link
US (1) US12054736B2 (en)
EP (1) EP3790578A4 (en)
JP (1) JP2021523712A (en)
CN (1) CN112512568A (en)
WO (1) WO2019217922A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201314A1 (en) 2022-04-13 2023-10-19 City Of Hope Cmv-hiv specific chimeric antigen receptor t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188961A1 (en) * 2002-05-16 2006-08-24 Paul Howley Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of modified vaccinia virus ankara
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835383B2 (en) 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
CN101831411A (en) 2002-05-16 2010-09-15 巴法里安诺迪克有限公司 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
WO2004093905A1 (en) 2003-04-16 2004-11-04 City Of Hope Human cytomegalovirus antigens expressed in mva and methods of use
US8326547B2 (en) * 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
CN103269713B (en) 2010-10-11 2016-01-20 诺华有限公司 Antigen delivery platform
JP6419695B2 (en) 2012-07-27 2018-11-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ MVA vaccine for delivery of UL128 complex and prevention of CMV infection
US11116834B2 (en) * 2016-10-19 2021-09-14 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188961A1 (en) * 2002-05-16 2006-08-24 Paul Howley Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of modified vaccinia virus ankara
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FELIX WUSSOW ET AL: "Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex", PLOS PATHOGENS, vol. 10, no. 11, 20 November 2014 (2014-11-20), US, pages e1004524, XP055256620, ISSN: 1553-7366, DOI: 10.1371/journal.ppat.1004524 *
LA ROSA CORINNA ET AL: "MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 129, no. 1, 5 January 2017 (2017-01-05), pages 114 - 125, XP086676883, ISSN: 0006-4971, [retrieved on 20201124], DOI: 10.1182/BLOOD-2016-07-729756 *
MANUEL E R ET AL: "Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 403, no. 2, 1 August 2010 (2010-08-01), pages 155 - 162, XP027063382, ISSN: 0042-6822, [retrieved on 20100514], DOI: 10.1016/J.VIROL.2010.04.015 *
See also references of WO2019217922A1 *
WANG Z ET AL: "Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 6, 10 February 2010 (2010-02-10), pages 1547 - 1557, XP026884482, ISSN: 0264-410X, [retrieved on 20091205], DOI: 10.1016/J.VACCINE.2009.11.056 *

Also Published As

Publication number Publication date
US20210062221A1 (en) 2021-03-04
WO2019217922A1 (en) 2019-11-14
US12054736B2 (en) 2024-08-06
JP2021523712A (en) 2021-09-09
EP3790578A1 (en) 2021-03-17
CN112512568A (en) 2021-03-16

Similar Documents

Publication Publication Date Title
WO2016144564A9 (en) Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
DK3407910T3 (en) RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) VACCINE AGAINST EQUINE ENCEPHALITIS VIRUS
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
EP3489354A4 (en) Recombinant vaccinia virus and use thereof
EP3481854A4 (en) Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof
EP3978601A4 (en) Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof
EP3838925A4 (en) Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof
EP3741845A4 (en) Recombinant vaccinia virus and pharmaceutical composition comprising same
EP4007600A4 (en) Vaccine compositions and methods of selecting antigens
EP3743084A4 (en) Recombinant viral vaccines
EP3903810A4 (en) Preparation including vaccine adjuvant
EP3875471A4 (en) Respiratory syncytial virus recombinant f protein and vaccine composition containing same
EP4003310A4 (en) Softshell capsule formulations, and methods of preparation and use thereof
EP3875110A4 (en) Modified cmv gb protein and cmv vaccine including same
IL290819A (en) Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
EP3790578A4 (en) Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof
EP3773711A4 (en) Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
MX2020009262A (en) Parapoxvirus vectors.
EP4031169A4 (en) Bee vaccines and methods of use
EP3452069A4 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
EP3763727A4 (en) Vaccine comprising epitope of heat shock protein, and use thereof
EP3804748A4 (en) Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof
IL286713A (en) Liposomal formulations, and methods of using and preparing thereof
EP3837280A4 (en) Recombinant hemoglobins and methods of preparation and use thereof
EP3866830A4 (en) Vaccine polypeptide compositions and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220310

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/20 20060101ALI20220303BHEP

Ipc: C07K 14/045 20060101ALI20220303BHEP

Ipc: C07K 14/005 20060101ALI20220303BHEP

Ipc: C12N 15/86 20060101ALI20220303BHEP

Ipc: A61K 39/245 20060101ALI20220303BHEP

Ipc: A61K 39/285 20060101ALI20220303BHEP

Ipc: A61K 39/12 20060101AFI20220303BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240426